Qizheng Tibetan Medicine (002287.SZ): Q1 net profit attributable to shareholders reached 95.18 million yuan, increasing by 25.77% year-on-year.

Gelonghui, April 24th: Qizheng Tibetan Medicine (QZTC, SZSE: 002287) released its Q1 2026 financial report. During the reporting period, the company achieved operating revenue of 405 million yuan, representing a year-on-year increase of 0.56%; net profit attributable to shareholders of the listed company amounted to 95.1791 million yuan, increasing by 25.77% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 75.590 million yuan, up 15.96% year-on-year; basic earnings per share were 0.1681 yuan.

Gelonghui FinanceApr 24 07:17

Qizheng Tibetan Medicine: First Quarter Report for 2026

SZSIApr 24 00:00 · Announcements

Qizheng Tibetan Medicine: 2025 Annual Report

SZSIApr 24 00:00 · Announcements

Qizheng Tibetan Medicine: Summary of the 2025 Annual Report

SZSIApr 24 00:00 · Announcements

Saudi Exchange Suspends Trading of Firms Over Delayed FY25 Results

MT NewswiresApr 1 17:45

Express News | Qizheng Tibetan Medicine: The company has sufficient reserves of saffron raw materials, and the obstruction of exports from Iran has not impacted the company’s production.

BreakingsMar 23 09:21